| 2024/04/19 08:01:11 | |
|---|---|
| Price | |
| 366.65 EUR | |
| Difference | -0.39% (-1.45) |
General attributes
| ISIN | US92532F1003 |
| Symbol | VRTX |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 95,501 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 367.65 EUR (28) |
| Ask (Ask size) | 369.00 EUR (28) |
| Open | 366.65 EUR |
| High | 366.65 EUR |
| Low | 366.65 EUR |
| Close (prev. day) | 368.10 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: VERTEX PHARMACEUTICALS INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/19 08:01:11 | |
|---|---|
| Price | |
| 366.65 EUR | |
| Difference | -0.39% (-1.45) |
General attributes
| ISIN | US92532F1003 |
| Symbol | VRTX |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 95,501 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 367.65 EUR (28) |
| Ask (Ask size) | 369.00 EUR (28) |
| Open | 366.65 EUR |
| High | 366.65 EUR |
| Low | 366.65 EUR |
| Close (prev. day) | 368.10 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +4.96% | +23.13% | +100.08% |
| Perf (abs.) | +17.40 | +69.15 | +184.12 |
| Beta | 0.75 | 0.69 | 0.60 |
| Volatility | 28.00 | 23.82 | 27.23 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 371.51 EUR (0) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 377.03 EUR (1) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 375.59 EUR (0) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 344.23 EUR (0) |
| YTD High | date | 407.10 EUR (2024/02/06) |
| YTD Low | date | 364.40 EUR (2024/04/11) |
| 52 Weeks High | date | 407.10 EUR (2024/02/06) |
| 52 Weeks Low | date | 292.35 EUR (2023/04/27) |
All listings for VERTEX PHARMACEUTICALS INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/04/18 | 17:35 | 367.90 EUR | 0.01 | 8 |
| Vienna Stock Exchange | 2024/04/18 | 17:32 | 367.00 EUR | 0.00 | 2 |
| Tradegate | 2024/04/18 | 22:26 | 369.65 EUR | 0.11 | 19 |
| Stuttgart | 2024/04/19 | 08:05 | 367.00 EUR | 0.00 | 1 |
| Nasdaq | 2024/04/18 | 22:00 | 393.48 USD | 373.70 | 27,133 |
| Munich | 2024/04/19 | 08:00 | 366.50 EUR | 0.00 | 1 |
| London Stock Exchange | 2024/04/04 | 16:36 | 409.12 USD | 0.00 | 1 |
| Hanover | 2024/04/19 | 08:01 | 366.65 EUR | 0.00 | 1 |
| Hamburg | 2024/04/19 | 08:01 | 366.70 EUR | 0.00 | 1 |
| Frankfurt | 2024/04/19 | 08:03 | 367.50 EUR | 0.00 | 1 |
| Euronext Milan MTF Trading After Hours | 2024/02/28 | 19:24 | 393.60 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2024/04/18 | 17:44 | 367.80 EUR | 0.00 | 1 |
| Duesseldorf | 2024/04/19 | 08:10 | 367.15 EUR | 0.00 | 1 |
| Berlin | 2024/04/19 | 08:08 | 366.95 EUR | 0.00 | 1 |
Company Logo
Contact Details
| VERTEX PHARMACEUTICALS INC. |
| - - |
| 50 Northern Avenue - 02210 Boston |
| Telefon: +1-617-341-6100 |
| Fax: + |
| E-mail: mediainfo@vrtx.com |
PDF Downloads
| Company report: VERTEX PHARMACEUTICALS INC. | |
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. |
Members of Management Board
| Jeffrey Leiden | Chairman of Board of Directors |
| Alan Garber | Member of Board of Directors |
| Sangeeta Bhatia | Member of Board of Directors |
| Bruce Sachs | Member of Board of Directors |
| Diana McKenzie | Member of Board of Directors |
| Lloyd Carney | Member of Board of Directors |
| Michel Lagarde | Member of Board of Directors |
| Nancy Thornberry | Member of Board of Directors |
| Suketu Upadhyay | Member of Board of Directors |
| Terrence Kearney | Member of Board of Directors |
| Reshma Kewalramani | Chairman of Managing Board |
| David Altshuler | Member of Executive Committee |
| Amit K. Sachdev | Member of Executive Committee |
| Bastiano Sanna | Member of Executive Committee |
| Carmen Bozic | Member of Executive Committee |
| Charles F. Wagner | Member of Executive Committee |
| E. Morrey Atkinson | Member of Executive Committee |
| Jonathan Biller | Member of Executive Committee |
| Nia Tatsis | Member of Executive Committee |
| Stuart A. Arbuckle | Member of Executive Committee |